Clinical Stage Biopharma Stocks
Pre-commercial life sciences entities focus on advancing proprietary drug candidates through rigorous human clinical trials to achieve regulatory approval and market exclusivity. These organizations operate with high research and development overhead, funding long-dated clinical timelines through dilutive equity rounds or strategic partnerships with established pharmaceutical majors.
As of Oct 23, 2026, Clinical Stage Biopharma has 152 US-listed companies worth $164B combined. The median member moved +0.5% over the past week; MANE led among the 25 largest at +27.5% and OCUL trailed at -5.4%.
Companies in Clinical Stage Biopharma
- BNTX – BioNTech SE, $22.9B
- PTGX – Protagonist Therapeutics Inc, $9B
- ARWR – Arrowhead Pharmaceuticals Inc, $8.2B
- TGTX – TG Therapeutics Inc, $8.1B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- IMVT – Immunovant Inc, $5.9B
- MANE – Veradermics, Incorporated, $5.8B
- BLTE – Belite Bio Inc ADR, $5.8B
- KOD – Kodiak Sciences Inc, $5.4B
- CGON – CG Oncology, Inc. Common stock, $5.3B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- SRRK – Scholar Rock Holding Corp, $5.1B
- CRSP – Crispr Therapeutics AG, $4.8B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- LQDA – Liquidia Technologies Inc, $3.6B
- VKTX – Viking Therapeutics Inc, $3.3B
- ELVN – Enliven Therapeutics Inc., $2.9B
- VRDN – Viridian Therapeutics Inc, $2.5B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- CLDX – Celldex Therapeutics Inc, $2.3B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- PHVS – Pharvaris BV, $2.1B
- BRVE – Braveheart Bio, Inc. Common Stock, $1.9B
- TRVI – Trevi Therapeutics Inc, $1.8B
- OCUL – Ocular Therapeutix Inc, $1.7B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- KRSA – Korsana Biosciences, Inc., $1.5B
- ANAB – AnaptysBio Inc, $1.5B
- IMCR – Immunocore Holdings Ltd, $1.5B
- INBX – Inhibrx Biosciences, Inc., $1.4B
- GHRS – GH Research PLC, $1.3B
- NKTR – Nektar Therapeutics, $1.2B
- DMRA – Damora Therapeutics, Inc., $1.2B
- SVRA – Savara Inc, $1B
- SPTX – Seaport Therapeutics, Inc. Common Stock, $986M
- AKTS – Aktis Oncology, Inc. Common stock, $890M
- ALMS – Alumis Inc, $885M
- ODTX – Odyssey Therapeutics, Inc. Common Stock, $871M
- IMMX – Immix Biopharma Inc, $803M
- LXRX – Lexicon Pharmaceuticals Inc, $783M
- IVA – Inventiva Sa, $770M
- OBX – Obsidian Therapeutics, Inc. Common Stock, $741M
- ACHV – Achieve Life Sciences Inc, $729M
- ANNX – Annexon Inc, $726M
- GYRE – Gyre Therapeutics Inc., $717M
- ABUS – Arbutus Biopharma Corp, $648M
- SGMT – Sagimet Biosciences Inc. Series A Common Stock, $633M
- ALT – Altimmune Inc, $595M
- AQST – Aquestive Therapeutics Inc, $579M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- CBIO – Crescent Biopharma, Inc., $532M
- MNPR – Monopar Therapeutics Inc, $498M
- AUTL – Autolus Therapeutics Ltd, $482M
- AGMB – AgomAb Therapeutics NV American Depositary Shares, $422M
- AVIR – Atea Pharmaceuticals Inc, $413M
- RZLT – Rezolute Inc, $396M
- KYTX – Kyverna Therapeutics, Inc. Common Stock, $395M
- TRXB – TRex Bio, Inc. Common stock, $384M
- CCCC – C4 Therapeutics Inc, $325M
- ARCT – Arcturus Therapeutics Holdings Inc, $308M
- SABS – SAB Biotherapeutics Inc, $262M
- CUVL – Clinuvel Pharmaceuticals Limited American Depositary Shares, $262M
- PALI – Palisade Bio Inc, $251M
- BCYC – Bicycle Therapeutics Ltd, $245M
- VCRE – Vicore Pharma Holding AB American Depositary Shares, $244M
- IFRX – InflaRx N.V., $223M
- KROS – Keros Therapeutics Inc, $222M
- ZNTL – Zentalis Pharmaceuticals Llc, $209M
- SION – Sionna Therapeutics, Inc. Common Stock, $187M
- YARW – Yarrow Bioscience Inc, $183M
- IVVD – Invivyd Inc., $182M
- ORMP – Oramed Pharmaceuticals Inc, $171M
- PEPG – PepGen Ltd, $166M
- NGEN – NervGen Pharma Corp., $166M
- UPB – Upstream Bio, Inc., $151M
- KRRO – Korro Bio, Inc., $141M
- RNA – Atrium Therapeutics, Inc. Common Stock, $130M
- SPRB – Spruce Biosciences, Inc. Common Stock, $116M
- GNLX – Genelux Corporation Common Stock, $114M
- AARD – Aardvark Therapeutics, Inc. Common Stock, $104M
- OKUR – OnKure Therapeutics, Inc., $97.6M
- ATRA – Atara Biotherapeutics Inc, $96M
- CRBP – Corbus Pharmaceuticals Holding, $85.5M
- ACRV – Acrivon Therapeutics, Inc. Common Stock, $81.8M
- OSTX – OS Therapies Incorporated, $75.8M
- MNOV – MediciNova Inc, $73.8M
- CING – Cingulate Inc, $63.4M
- GOSS – Gossamer Bio Inc, $59.9M
- CNTB – Connect Biopharma Holdings Ltd, $56.7M
- LONA – LeonaBio, Inc., $49M
- TVGN – Tevogen Bio Holdings Inc., $46M
- SER – Serina Therapeutics Inc, $45.5M
- DWTX – Dogwood Therapeutics, Inc., $42.5M
- VERU – Veru Inc, $41.9M
- NSRX – Nasus Pharma Ltd., $37.2M
- EDSA – Edesa Biotech Inc, $36.1M
- IRLA – IRulya Therapeutics Inc., $35M
- ELUT – Elutia Inc., $34.2M
- EYPT – EyePoint, Inc, $34M
- NNVC – NanoViricides Inc, $33.2M
- MIRA – MIRA Pharmaceuticals, Inc. Common Stock, $28M
- ABVC – ABVC Biopharma Inc, $26.7M
- KYNB – Kyntra Bio, Inc., $23.8M
- PBM – Psyence Biomedical Ltd. Common Shares, $19.1M
- NEUP – Neuphoria Therapeutics Inc, $18.8M
- LPCN – Lipocine Inc, $16.9M
- RADX – Radiopharm Theranostics Limited American Depositary Shares, $15.8M
- QNTM – Quantum BioPharma Ltd., $14.6M
- GTBP – GT Biopharma Inc, $14.5M
- HIND – Vyome Holdings, Inc., $13.8M
- DARE – Dare Bioscience Inc, $13.5M
- FEMY – Femasys Inc, $13.1M
- CNSY – Cerenome, Inc., $12.9M
- ADIL – Adial Pharmaceuticals Inc, $12.2M
- AEON – AEON Biopharma, Inc., $11.6M
- LSTA – Lisata Therapeutics Inc., $11.2M
- RGNT – Regentis Biomaterials Ltd., $10.3M
- PTN – Palatin Technologies, Inc. Common Stock, $9.9M
- IMRN – Immuron Ltd ADR, $9.4M
- VTGN – VistaGen Therapeutics Inc, $8.9M
- ENSC – Ensysce Biosciences Inc, $7.8M
- CURX – Curanex Pharmaceuticals Inc Common Stock, $7.5M
- SKYE – Skye Bioscience, Inc. Common Stock, $7.2M
- ALZN – Alzamend Neuro Inc, $6.5M
- RVPH – Reviva Pharmaceuticals Holdings Inc., $6.5M
- MBRX – Moleculin Biotech Inc, $6.3M
- APUS – Apimeds Pharmaceuticals US, Inc., $6.1M
- CANF – Can Fite Biopharma Ltd ADR, $5.9M
- TRAW – Traws Pharma Inc, $5.7M
- BGMS – Bio Green Med Solution, Inc., $5.5M
- ADXN – Addex Therapeutics Ltd, $5.4M
- GLMD – Galmed Pharmaceuticals Ltd, $4.9M
- PPCB – Propanc Biopharma, Inc. Common Stock, $4.8M
- GRI – GRI Bio Inc., $4.2M
- CVKD – Cadrenal Therapeutics, Inc. Common Stock, $4.1M
- EOCN – Eocene Ltd., $3.8M
- KALA – Kala Pharmaceuticals Inc, $3.7M
- XRTX – XORTX Therapeutics Inc, $2.3M
- XAIR – Beyond Air Inc, $2.2M
- ATXI – Avenue Therapeutics Inc, $1.4M
- PTIX – Protagenic Therapeutics, $1.4M
- LABT – Lakewood-Amedex Biotherapeutics Inc. Common Stock, $1.4M
- SRNE – Sorrento Therape, $441,024
- LYRA – Lyra Therapeutics Inc, $337,227
- CDT – Conduit Pharmaceuticals Inc., $209,159
- OCEA – Ocean Biomedical Inc., $185,892
- TRVN – Trevena Inc, $57,010
- CARM – Carisma Therapeutics Inc., $20,922
- STAB – Statera Biopharma Inc, $7,141
- ARDS – Aridis Pharmaceuticals Inc, $4,457
- ADRX – ADARx Pharmaceuticals, Inc. Common Stock
- RTSN – Retension Pharmaceuticals, Inc.